Trials / Completed
CompletedNCT02234089
Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 461 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to detect factors influencing decision making for treatment pathways of hormone-naïve prostate cancer patients with and without comorbidities receiving medicinal androgen deprivation therapy (Degarelix or LHRH agonists).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Degarelix | According to medical practice |
| DRUG | LHRH agonist (Leuprorelinacetat, Goserelinacetat, Buserelinacetat, Triptorelinacetat) | According to medical practice |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2019-06-30
- Completion
- 2019-06-30
- First posted
- 2014-09-09
- Last updated
- 2019-07-05
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02234089. Inclusion in this directory is not an endorsement.